Patents by Inventor Darrell J. Irvine

Darrell J. Irvine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11034752
    Abstract: The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 15, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Darrell J. Irvine, Yiran Zheng, Li Tang
  • Patent number: 11026894
    Abstract: Disclosed herein are lipid nanoparticles comprising 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000](DSPE-PEG2000), compositions including such lipid nanoparticles, and methods of treatment using such lipid nanoparticles and compositions.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: June 8, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Ron Weiss, Tasuku Kitada, Mariane Melo, Yuan Zhang
  • Patent number: 10888603
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 12, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Darrell J. Irvine, Cary Francis Opel, Kelly Dare Moynihan, Jennifer R. Cochran, Byron Hua Kwan
  • Publication number: 20200405850
    Abstract: The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: December 31, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Darrell J. IRVINE, Karl Dane WITTRUP, Tyson MOYER, Yash AGARWAL
  • Publication number: 20200377576
    Abstract: Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Darrell J. Irvine, Dan H. Barouch, Arup K. Chakraborty, Dariusz Murakowski, Bruce D. Walker, John Barton, Andrew Ferguson
  • Publication number: 20200377929
    Abstract: The present disclosure relates to a device, comprising a base and a plurality of microneedles attached to the base, wherein each microneedle has an outer surface; the outer surface of at least one microneedle being coated with a composition comprising at least one polymer and least one Peptide Nucleic Acid (PNA). The present disclosure additionally relates to a method of detecting an analyte in interstitial fluid (ISF), comprising contacting the device to a subject, for example, to human skin.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Inventors: Darrell J. Irvine, Jason Y.H. Chang, Sylvain Ladame, Dana Al Sulaiman
  • Publication number: 20200360482
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Application
    Filed: February 19, 2020
    Publication date: November 19, 2020
    Inventors: Li TANG, Darrell J. IRVINE
  • Publication number: 20200345853
    Abstract: Provided herein are methods for stimulating an immune response to a target cell population or a target tissue in a subject by administering to the subject a composition comprising an amphiphilic ligand conjugate. Such an amphiphilic ligand conjugate can comprise a lipid, one or more cargos (e.g., a CAR ligand, a chimeric cytokine receptor target, a chimeric co-stimulation receptor target, a synNotch receptor target), and optionally a linker.
    Type: Application
    Filed: March 20, 2020
    Publication date: November 5, 2020
    Inventors: Darrell J. IRVINE, Peter C. DEMUTH
  • Publication number: 20200281994
    Abstract: The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
    Type: Application
    Filed: January 10, 2020
    Publication date: September 10, 2020
    Applicants: Massachusetts Institute of Technology, The Ohio State University
    Inventors: Darrell J. Irvine, Karl Dane Wittrup, Ron Weiss, Yingzhong Li, Noor Momin, Yizhou Dong
  • Publication number: 20200230225
    Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Inventors: Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Darrell J. IRVINE, Ron WEISS, Ely Blanton PORTER, Mariane Bandeira MELO, Tasuku KITADA
  • Publication number: 20200230221
    Abstract: The disclosure describes amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR) ligand, a lipid (diacyl lipid), a linker (hydrophilic polymers, hydrophilic amino acids, polysaccharides), compositions and methods of using the constructs are claimed, for example, to stimulate proliferation of CAR expressing cells.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 23, 2020
    Inventors: Darrell J. IRVINE, Leyuan MA
  • Publication number: 20200230208
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Application
    Filed: November 22, 2019
    Publication date: July 23, 2020
    Inventors: Chensu WANG, Karl Dane WITTRUP, Darrell J. IRVINE
  • Publication number: 20200222332
    Abstract: Disclosed herein are lipid nanoparticles having a specific composition, compositions including such lipid nanoparticles, and methods of treatment using such lipid nanoparticles and compositions.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Ron Weiss, Tasuku Kitada, Mariane Melo, Yuan Zhang
  • Publication number: 20200224174
    Abstract: The disclosure provides methods for an in vitro evolution technique to identify and characterize mutations in the non-structural genes of an alphavirus replicon that increase the strength and persistence of expression of the replicon genome. Also provided herein are in vivo methods for administering to an animal model a mutated alphavirus replicon that codes for a gene of experimental or therapeutic interest in the subgenome of the alphavirus replicon. The mutations identified herein improve the therapeutic potential of self-replicating RNA, which may have implications for cancer immunotherapy and beyond, e.g., for vaccination or gene therapy.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Ron Weiss, Yingzhong Li
  • Publication number: 20200188475
    Abstract: The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 18, 2020
    Inventors: Ellis L. Reinherz, Kyoung Joon Oh, Mikyung Kim, Gerhard Wagner, Zhen-Yu J Sun, Darrell J. Irvine, Anna Bershteyn
  • Publication number: 20200179528
    Abstract: The present disclosure provides particles with a polymeric core containing a pharmaceutically active agent; and an antibody fragment conjugated to the surface of the particle, wherein the antibody fragment targets an endogenous immune cell subset (e.g., an endogenous T-cell or a myeloid-derived suppressor cell). The present invention provides methods for forming and methods for using the particles. The particles described herein may be useful in treating and/or preventing proliferative disease, inflammatory disease, or neoplastic disorders (e.g., cancer, autoimmune diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a particle described herein.
    Type: Application
    Filed: December 23, 2016
    Publication date: June 11, 2020
    Applicants: Dana-Farber Cancer Institute, Inc., Massachusetts Institute of Technology
    Inventors: Michael Solomon Goldberg, Daniela Schmid, Darrell J. Irvine, Kai Wucherpfennig
  • Publication number: 20200085756
    Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.
    Type: Application
    Filed: July 12, 2019
    Publication date: March 19, 2020
    Inventors: Darrell J. Irvine, Murillo Silva, Shane Crotty, Yu Kato
  • Patent number: 10588942
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 17, 2020
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Li Tang, Darrell J. Irvine
  • Publication number: 20200016238
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Application
    Filed: June 25, 2019
    Publication date: January 16, 2020
    Inventors: Li TANG, Darrell J. IRVINE
  • Publication number: 20200000931
    Abstract: The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (PNA) oligomer conjugated to a lipid, wherein the PNA oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases.
    Type: Application
    Filed: April 10, 2019
    Publication date: January 2, 2020
    Inventors: Darrell J. IRVINE, Eric DANE